{"log_id": 7718455686882209932, "direction": 0, "words_result_num": 45, "words_result": [{"probability": {"variance": 0.007383, "average": 0.969496, "min": 0.674283}, "location": {"width": 259, "top": 237, "height": 23, "left": 216}, "words": "①过敏性反应和急性过敏反应"}, {"probability": {"variance": 0.007717, "average": 0.960724, "min": 0.599176}, "location": {"width": 832, "top": 268, "height": 24, "left": 214}, "words": "接受培门冬酶治疗的患者可能发生意性过敏反应;尤其有过左旋门冬酰胺安酶过敏史的崽者儿率更"}, {"probability": {"variance": 0.00467, "average": 0.970212, "min": 0.624419}, "location": {"width": 871, "top": 295, "height": 28, "left": 176}, "words": "高。给药后应在复苏装置及其他必备条件下(例如肾上腺素,氧气,静脉注射类固,抗胺药)观"}, {"probability": {"variance": 0.019476, "average": 0.936447, "min": 0.369711}, "location": {"width": 859, "top": 328, "height": 26, "left": 176}, "words": "察1小时以防发生过敏反应。患者发生严重急性过敏反应时应停止给药,给予抗细药物、肾上腺"}, {"probability": {"variance": 8.2e-05, "average": 0.993419, "min": 0.967946}, "location": {"width": 320, "top": 360, "height": 24, "left": 176}, "words": "氧气和静脉内注射类固醇等救治措施"}, {"probability": {"variance": 0.003821, "average": 0.976746, "min": 0.753542}, "location": {"width": 831, "top": 390, "height": 27, "left": 215}, "words": "②血栓严重血栓现象,包括矢状窦血栓可能发生在培门冬酶给药患者身上。发生时应停止使用该"}, {"probability": {"variance": 0, "average": 0.948066, "min": 0.948066}, "location": {"width": 24, "top": 422, "height": 23, "left": 176}, "words": "药"}, {"probability": {"variance": 0.000798, "average": 0.990845, "min": 0.856885}, "location": {"width": 814, "top": 451, "height": 27, "left": 213}, "words": "③胰腺炎给予培门冬酶可发生胰腺炎。可以腹部疼痛作为胰腺炎的征兆。发生时停止使用该药"}, {"probability": {"variance": 0.013106, "average": 0.964078, "min": 0.435256}, "location": {"width": 722, "top": 481, "height": 26, "left": 213}, "words": "④葡萄糖耐量降低给予培门冬酶可发生葡萄糖耐降低,且某些情况下是不可的"}, {"probability": {"variance": 0.012131, "average": 0.962111, "min": 0.413902}, "location": {"width": 828, "top": 512, "height": 27, "left": 214}, "words": "⑤凝血障碍给予培门冬酶的患者或可发生凝血酶原时间延长,部分促凝血活时间延长,低纤维"}, {"probability": {"variance": 0.005313, "average": 0.984728, "min": 0.509676}, "location": {"width": 867, "top": 541, "height": 30, "left": 175}, "words": "蛋白原血症等凝血相关现象。给药期及给药后应定期检测相关凝血参数是否超过基线。对于有急性凝"}, {"probability": {"variance": 0.000102, "average": 0.993575, "min": 0.963233}, "location": {"width": 494, "top": 574, "height": 24, "left": 175}, "words": "血征兆的患者在给药前应用新鲜冷冻的血浆替代凝血因子"}, {"probability": {"variance": 0, "average": 0.999365, "min": 0.998751}, "location": {"width": 121, "top": 604, "height": 24, "left": 214}, "words": "使用注意事项"}, {"probability": {"variance": 0.002517, "average": 0.984321, "min": 0.713667}, "location": {"width": 824, "top": 634, "height": 28, "left": 211}, "words": "1本品冷冻结冰后不能使用。冷冻后药物的外观虽然没有明显的改变,但是药物的活性已经消失"}, {"probability": {"variance": 5.8e-05, "average": 0.996862, "min": 0.96092}, "location": {"width": 832, "top": 665, "height": 29, "left": 211}, "words": "2使用前通过肉眼检查颗粒物质、混浊和变色。如发现溶液中有微粒、浑浊、污点、须扔掉该药"}, {"probability": {"variance": 0, "average": 0.958775, "min": 0.958775}, "location": {"width": 22, "top": 698, "height": 22, "left": 174}, "words": "品"}, {"probability": {"variance": 1e-06, "average": 0.999361, "min": 0.997582}, "location": {"width": 226, "top": 726, "height": 24, "left": 180}, "words": "【孕妇及哺乳期妇女用药】"}, {"probability": {"variance": 0.000175, "average": 0.98668, "min": 0.973442}, "location": {"width": 43, "top": 758, "height": 22, "left": 212}, "words": "妊娠"}, {"probability": {"variance": 0.00248, "average": 0.98477, "min": 0.774025}, "location": {"width": 825, "top": 785, "height": 32, "left": 211}, "words": "培门冬酶没有进行动物生殖毒性研究。目前不知培门冬酶在孕妇是否会导致胎儿伤害,以及是否"}, {"probability": {"variance": 0.001606, "average": 0.987088, "min": 0.797743}, "location": {"width": 593, "top": 819, "height": 26, "left": 173}, "words": "影响生殖能力。培门冬酶应该在明确必须给药的情况应用于妊娠妇女"}, {"probability": {"variance": 0.002266, "average": 0.952361, "min": 0.904755}, "location": {"width": 41, "top": 851, "height": 22, "left": 213}, "words": "哺乳"}, {"probability": {"variance": 0.00232, "average": 0.988778, "min": 0.688086}, "location": {"width": 824, "top": 879, "height": 28, "left": 212}, "words": "培门冬酶是否分泌于人类的乳汁中不得而知。因为许多药物会分泌到乳汁中,并县培门冬酶对哺"}, {"probability": {"variance": 1.7e-05, "average": 0.997777, "min": 0.982308}, "location": {"width": 704, "top": 912, "height": 26, "left": 172}, "words": "乳幼儿有潜在的危害,要根据药物对母亲的重要性来权衡是否对哺乳母亲使用药物"}, {"probability": {"variance": 9e-06, "average": 0.997046, "min": 0.992442}, "location": {"width": 107, "top": 944, "height": 24, "left": 179}, "words": "【儿童用药】"}, {"probability": {"variance": 0.004984, "average": 0.979726, "min": 0.557904}, "location": {"width": 804, "top": 976, "height": 26, "left": 222}, "words": "持本品注册的临床试验主要在18岁以下患者中进行,具体见【临床试验】和【不良反应】项"}, {"probability": {"variance": 9e-06, "average": 0.996943, "min": 0.990896}, "location": {"width": 107, "top": 1008, "height": 24, "left": 179}, "words": "【老年用药】"}, {"probability": {"variance": 0.005923, "average": 0.982434, "min": 0.496222}, "location": {"width": 830, "top": 1036, "height": 29, "left": 210}, "words": "培门冬酶没有进行65岁或更大年龄患者的临床研究,尚不明确老年患者的反应是否与儿童或年青"}, {"probability": {"variance": 5.2e-05, "average": 0.996189, "min": 0.980083}, "location": {"width": 120, "top": 1070, "height": 25, "left": 172}, "words": "患者存在差异"}, {"probability": {"variance": 1.5e-05, "average": 0.995987, "min": 0.987924}, "location": {"width": 146, "top": 1101, "height": 25, "left": 178}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.000274, "average": 0.991714, "min": 0.937397}, "location": {"width": 649, "top": 1129, "height": 25, "left": 211}, "words": "未进行这方面研究,也未见培门冬酶或类似品种与其它药物相互作用的报道"}, {"probability": {"variance": 0.003046, "average": 0.961831, "min": 0.852167}, "location": {"width": 108, "top": 1162, "height": 23, "left": 176}, "words": "【药物过量】"}, {"probability": {"variance": 0.014695, "average": 0.945667, "min": 0.418327}, "location": {"width": 832, "top": 1191, "height": 26, "left": 208}, "words": "国外文献报道,三名患者静脉注射 Caspar-10,000IU/m。1位患者出现轻度肝酶增加。1位患"}, {"probability": {"variance": 0.000268, "average": 0.995085, "min": 0.90409}, "location": {"width": 824, "top": 1222, "height": 25, "left": 216}, "words": "者在开始注射10分钟后出现皮疹,通过使用抗组胺药物和减慢输注速度得到控制。另1位患者"}, {"probability": {"variance": 3.4e-05, "average": 0.996156, "min": 0.981535}, "location": {"width": 156, "top": 1254, "height": 24, "left": 220}, "words": "未出现任何副反应"}, {"probability": {"variance": 0.000293, "average": 0.988983, "min": 0.951644}, "location": {"width": 105, "top": 1286, "height": 24, "left": 179}, "words": "【临床试验】"}, {"probability": {"variance": 1e-05, "average": 0.99812, "min": 0.990694}, "location": {"width": 137, "top": 1317, "height": 23, "left": 211}, "words": "◇国外临床研究"}, {"probability": {"variance": 8e-06, "average": 0.998837, "min": 0.988148}, "location": {"width": 362, "top": 1346, "height": 27, "left": 208}, "words": "急性淋巴细胞白血病的一线治疗临床研究"}, {"probability": {"variance": 0.006683, "average": 0.978055, "min": 0.507224}, "location": {"width": 830, "top": 1375, "height": 28, "left": 210}, "words": "在一项开放、多中心、随机、阳性药对照的试验中评价了 Oncaspar”的安全性和有效性。该试验中"}, {"probability": {"variance": 0.003704, "average": 0.975174, "min": 0.711898}, "location": {"width": 871, "top": 1407, "height": 27, "left": 169}, "words": "入组了118位先前未曾治疗过的1-9岁的标危的急性淋巴细胞白血病患者,随机分为 Oncaspar组和大肠"}, {"probability": {"variance": 0.00388, "average": 0.976663, "min": 0.649808}, "location": {"width": 871, "top": 1440, "height": 24, "left": 169}, "words": "杆菌左旋门冬酰胺酶组(联合治疗方案的组分之一)进行治疗。 Oncaspar的剂量为2500IU/m3,于为"}, {"probability": {"variance": 0.000443, "average": 0.993907, "min": 0.890716}, "location": {"width": 868, "top": 1471, "height": 26, "left": 171}, "words": "期4周的诱导期第3天以及两个为期8周的强化治疗期第3天进行肌肉注射。天然大肠杆菌左旋门冬酰胺"}, {"probability": {"variance": 0.00392, "average": 0.97822, "min": 0.608502}, "location": {"width": 822, "top": 1502, "height": 27, "left": 167}, "words": "酶给药剂量为600IU/m,在诱导期每周给药3次,连续3周;在两个延迟强化治疗期分别给药6次"}, {"probability": {"variance": 4.4e-05, "average": 0.996381, "min": 0.972032}, "location": {"width": 830, "top": 1533, "height": 27, "left": 208}, "words": "主要疗效指标是检测 Oncaspar组和大肠杆菌左旋门冬酰胺酶组患者血清门冬酰胺浓度水平(减少"}, {"probability": {"variance": 7.9e-05, "average": 0.995757, "min": 0.953375}, "location": {"width": 866, "top": 1566, "height": 25, "left": 170}, "words": "的程度和时间长短)。达到指定门冬酰胺的目标浓度是≤1M两个临床研究组患者在三个治疗阶"}, {"probability": {"variance": 2.1e-05, "average": 0.997725, "min": 0.981077}, "location": {"width": 319, "top": 1597, "height": 25, "left": 168}, "words": "段达到这个目标浓度的比例是一样的"}], "language": 3}